ELM-2: a phase 2 trial assessing the safety of odronextamab in adults with relapsed or refractory B-cell non-Hodgkin lymphoma

This trial is testing the activity of odronetamab in people with relapsed or refractory B-cell non-Hodgkin lymphoma.

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT03888105

Trial aim and background 

The aim of this trial is to find out the safety and efficacy of odronextamab in people whose B-cell non-Hodgkin lymphoma has relapsed or not responded to treatment (refractory lymphoma). The types of B-cell non-Hodgkin lymphoma included in this trial are:

Who can enter

Adults with certain B-cell lymphomas that have relapsed or not responded to treatment may be eligible for this trial.

Locations

Recruitment is taking place in the following UK locations:

  • University Hospital of Wales, Cardiff
  • Kings College Hospital, London
  • Derriford Hospital, Plymouth
  • The Royal Marsden Hospital, Sutton
  • Royal Cornwall Hospital, Truro

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/ct2/show/NCT03888105

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.